To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
| DRAVP ID | Name | Sequence | Target Organism | Pubmed/Patent ID |
|---|---|---|---|---|
| DRAVPe02166 | Peptide aldehyde 4 | NSTSQ | SARS-CoV | 21854807 |
| DRAVPe02167 | Tetrapeptide aldehyde | TVFH | SARS-CoV | 22014094 |
| DRAVPe02168 | Oligopeptide 1 | VIQY | SARS-CoV-2 | 32520031 |
| DRAVPe02169 | Oligopeptide 2 | ICIY | SARS-CoV-2 | 32520031 |
| DRAVPe02170 | Oligopeptide 3 | PISQF | SARS-CoV-2 | 32520031 |
| DRAVPe02171 | Oligopeptide 4 | VISAW | SARS-CoV-2 | 32520031 |
| DRAVPe02172 | Oligopeptide 5 | AIPAW | SARS-CoV-2 | 32520031 |
| DRAVPe02173 | Oligopeptide 6 | PVSQF | SARS-CoV-2 | 32520031 |
| DRAVPe02174 | K12 | GGASCCLYCRCH | SARS-CoV | 22659295 |
| DRAVPe02175 | K29 | FGGASCCLYCRCHIDHPNPKGFCDLKGKY | SARS-CoV | 22659295 |
| DRAVPe02290 | Plantaricin NC8 α | LTTKLWSSWGYYLGKKARWNLKHPYVQF | LGTV,IAV,HIV-1.SARS-CoV-2 | 36449554 |
| DRAVPe02292 | Protegrin 2 | RGGRLCYCRRRFCICV | HSV-1,HSV-2.SARS-CoV-2 | 8647100,37576748 |
| DRAVPe02673 | P8 | PSSKRFQPFQQFGRDVSDFT | SARS-CoV | 15811330 |
| DRAVPe02686 | sHR1 | AYRFNGIQVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLIT | SARS-CoV | 15150417 |
| DRAVPe02691 | Mucroporin | LFGLIPSLIGGLVSAFK | MV,SARS-CoV,IAV | 21620914 |
| DRAVPe02694 | P1 | TSSMRGVYYPDEIFRSDTLYL | SARS-CoV | 15811330 |
| DRAVPe02695 | P2 | KSNVVRGWVFGSTMNNKSQS | SARS-CoV | 15811330 |
| DRAVPe02696 | P3 | YKGYQPIDVVRDLPSGFNTL | SARS-CoV | 15811330 |
| DRAVPe02697 | P4 | TDAVDCSQNPLAELKCSVKSF | SARS-CoV | 15811330 |
| DRAVPe02698 | P5 | KGIYQTSNFRVVPSGDVVRF | SARS-CoV | 15811330 |
| DRAVPe02699 | P6 | TKFPSVYAWERKKISNCVAD | SARS-CoV | 15811330 |
| DRAVPe02700 | P7 | YNYKYRYLRHGKLRPFERDI | SARS-CoV | 15811330 |
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.